COMP <GO>
IBRX vs KRYS // NET PROFIT MARGIN
ImmunityBio Inc. (NASDAQ) VS. Krystal Biotech Inc. (NASDAQ) • 15-METRIC TALLY: IBRX 4
— KRYS 7
▲ NET PROFIT MARGIN LEADER: KRYS
LAST: $8.74 (-0.79%) • MKT CAP: $9.26B
net-margins
-60.00%
LAST: $324.55 (+0.97%) • MKT CAP: $9.61B
net-margins
52.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IBRX VS. KRYS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IBRX | KRYS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.30% | 16.50% | -43.80 | KRYS | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 53.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.33% | 1.97% | -5.30 | KRYS | /fcf-yield <GO> |
| Operating Margin | -60.00% | 41.50% | -101.50 | KRYS | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -60.00% | 52.60% | -112.60 | KRYS | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 33.90% | +146.10 | IBRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 26.00 | -25.55 | KRYS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | KRYS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.0 | 48.2 | +0.80 | IBRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 0.91 | +0.14 | IBRX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.0x | 39.4x | -10.40 | IBRX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.26B | $9.61B | -$343.3M | KRYS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IBRX REV | KRYS REV | IBRX GROSS % | KRYS GROSS % | IBRX FCF | KRYS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $113.3M | $389.1M | 99.3% | — | -$308.8M | $188.9M |
| FY 2024 | $14.7M | $290.5M | 100.0% | — | -$398.1M | $119.2M |
| FY 2023 | $622.0K | $50.7M | — | — | -$366.8M | -$91.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IBRX // BETA 1.05
KRYS // BETA 0.91